{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li Y"],"funding":["U.S. Department of Defense","National Cancer Institute","NCI NIH HHS"],"pagination":["2100160"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9269983"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(1)"],"pubmed_abstract":["Radiotherapy (RT) has demonstrated synergy with immune checkpoint blockade (ICB) in preclinical models. However, its potential as an immunoadjuvant is limited by low immunogenicity at low radiation doses and immunosuppression at high radiation doses. It is hypothesized that radiosensitizers can enhance both the anticancer and immunogenic effects of low-dose radiation. Herein the authors report the antitumor immunity of combined RT and immunotherapy with dimethylaminomicheliolide (DMAMCL), a prodrug of the anti-inflammatory sesquiterpene lactone micheliolide (MCL). DMAMCL sensitized cancer cells to a single fraction of RT in vitro by inducing apoptosis and DNA double-strand breaks. DMAMCL with 5 fractions of 2 Gy focal X-ray irradiation led to significant anticancer efficacy in subcutaneous"],"journal":["Advanced therapeutics"],"pubmed_title":["Dimethylaminomicheliolide Sensitizes Cancer Cells to Radiotherapy for Synergistic Combination with Immune Checkpoint Blockade."],"pmcid":["PMC9269983"],"funding_grant_id":["U01‐CA198989","PC170934P2","R01 CA223184","U01 CA198989","R01 CA253655","R01 CA216436","P30 CA014599","1R01CA253655"],"pubmed_authors":["Guo N","Li Y","Ni K","Culbert A","Han W","Lin W","Weichselbaum RR","Chan C","Luo T"],"additional_accession":[]},"is_claimable":false,"name":"Dimethylaminomicheliolide Sensitizes Cancer Cells to Radiotherapy for Synergistic Combination with Immune Checkpoint Blockade.","description":"Radiotherapy (RT) has demonstrated synergy with immune checkpoint blockade (ICB) in preclinical models. However, its potential as an immunoadjuvant is limited by low immunogenicity at low radiation doses and immunosuppression at high radiation doses. It is hypothesized that radiosensitizers can enhance both the anticancer and immunogenic effects of low-dose radiation. Herein the authors report the antitumor immunity of combined RT and immunotherapy with dimethylaminomicheliolide (DMAMCL), a prodrug of the anti-inflammatory sesquiterpene lactone micheliolide (MCL). DMAMCL sensitized cancer cells to a single fraction of RT in vitro by inducing apoptosis and DNA double-strand breaks. DMAMCL with 5 fractions of 2 Gy focal X-ray irradiation led to significant anticancer efficacy in subcutaneous","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-06-04T04:57:39.204Z","creation":"2025-04-04T20:07:04.72Z"},"accession":"S-EPMC9269983","cross_references":{"pubmed":["35812344"],"doi":["10.1002/adtp.202100160"]}}